RetinalGenix (RTGN) CFO Michael Cory Zwerling resigns with immediate effect

Rhea-AI Filing Summary

RetinalGenix Technologies Inc. reported that its Chief Financial Officer, Michael Cory Zwerling, resigned from his position, effective immediately on March 22, 2026. The company did not provide additional details about the circumstances of his departure or plans for a successor in this report.

Positive

• None.

Negative

• Chief Financial Officer resigned effective immediately on March 22, 2026, with no transition details provided, creating potential uncertainty around financial leadership and oversight until a replacement or interim plan is disclosed.

Insights

Corporate governance and leadership analyst

Sudden CFO resignation introduces leadership uncertainty at RetinalGenix.

The company disclosed that Chief Financial Officer Michael Cory Zwerling resigned effective immediately on March 22, 2026. A CFO oversees financial reporting, capital planning, and controls, so any abrupt change in this role can matter for how reliably financial information is produced.

The disclosure does not mention a transition plan, interim replacement, or reasons for the resignation. That absence of detail can raise questions about continuity in financial management and internal processes until further information is provided in subsequent company communications or filings.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

false 0001836295 0001836295 2026-03-22 2026-03-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 22, 2026

RETINALGENIX TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Delaware		333-258528		82-3936890
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

1450 North McDowell Boulevard, Suite 150

Petaluma, CA 94954

(Address of principal executive offices, including zip code)

(415) 578-9583

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 22, 2026, Michael Cory Zwerling, the Chief Financial Officer of RetinalGenix Technologies Inc. (the “Company”), notified the Company of his decision to resign, effective immediately, from his position as the Company’s Chief Financial Officer.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	RETINALGENIX TECHNOLOGIES INC.
Date: March 26, 2026	By:	/s/ Jerry Katzman
		Jerry Katzman
		Chief Executive Officer

-3-

FAQ

What did RetinalGenix Technologies Inc. (RTGN) announce in this 8-K filing?

RetinalGenix Technologies Inc. announced that its Chief Financial Officer, Michael Cory Zwerling, resigned effective immediately on March 22, 2026. The filing focuses on this leadership change and does not include additional financial results or transaction details.

Who resigned from RetinalGenix Technologies Inc. (RTGN) and when was it effective?

Chief Financial Officer Michael Cory Zwerling resigned from RetinalGenix Technologies Inc., effective immediately on March 22, 2026. The company reported this leadership change under Item 5.02, which covers departures of certain officers and related matters.

Does the RetinalGenix (RTGN) 8-K explain why the CFO resigned?

The 8-K states that CFO Michael Cory Zwerling notified the company of his decision to resign, effective immediately on March 22, 2026. It does not describe any reasons or circumstances surrounding his departure in the provided text.

Did RetinalGenix (RTGN) name a new or interim CFO in this filing?

No successor is identified in this filing. The 8-K only discloses that Chief Financial Officer Michael Cory Zwerling resigned effective immediately on March 22, 2026, without mentioning an interim or permanent replacement within the disclosed content.

Which SEC item does RetinalGenix (RTGN) use for the CFO resignation disclosure?

RetinalGenix uses Item 5.02, titled “Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,” to report CFO Michael Cory Zwerling’s resignation effective March 22, 2026.

Who signed the RetinalGenix (RTGN) 8-K reporting the CFO’s resignation?

The 8-K is signed on behalf of RetinalGenix Technologies Inc. by Jerry Katzman, who is identified as the company’s Chief Executive Officer. The signature block confirms the filing was authorized by senior management.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB